United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 13

Name: Pharmaceutical Preparations Stocks in USA: Revenue Cohort 13 comparison snapshot
Creator: Fliar BI Prism

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderCytokinetics · 58

Strongest available pathElite Pharma · +480.0%

Widest latest marginSIGA Technologies · 24.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CYTK · Nasdaq

Cytokinetics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1997San Francisco, California$10.02B market cap

View full Companies Radar profile

58Moderate

Snapshot price$72.09as of page date

Monthly-close return+136.3%five-year window

FY2025 revenue$0.09BCYTOKINETICS INC

Net margin-891.6%FY2025

P/E snapshot-16.2xone ratio, not a verdict

Prism attention29.7%share across these five

Filing track recordRevenue, USD billions

+25.0%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 5.7%

52-week position63% through range

$44.91$88.31

News mentions2.1K

Community mentions24partial coverage

U.S.-scope patents1376

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal87/100
Management stability90/100
Market position10/100
Capital-event signal81/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 2 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2NRIX · Nasdaq

Nurix Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2009San Francisco, California$2.72B market cap

View full Companies Radar profile

56Moderate

Snapshot price$26.21as of page date

Monthly-close return-16.5%five-year window

FY2025 revenue$0.08BNurix Therapeutics, Inc.

Net margin-314.9%FY2025

P/E snapshot-18.2xone ratio, not a verdict

Prism attention13.2%share across these five

Filing track recordRevenue, USD billions

+54.0%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 54.0%

52-week position90% through range

$8.20$28.23

News mentions910

Community mentions4partial coverage

U.S.-scope patents259

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal88/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3ELTP · OTC

Elite Pharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1998Alhambra, California$312.4M market cap

View full Companies Radar profile

50Moderate

Snapshot price$0.29as of page date

Monthly-close return+480.0%five-year window

FY2025 revenue$0.08BELITE PHARMACEUTICALS INC /NV/

Net margin-5.1%FY2025

P/E snapshot5.8xone ratio, not a verdict

Prism attention0.0%share across these five

Filing track recordRevenue, USD billions

+231.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Revenue derived as cost of revenue plus gross profit for FY2021 · CAGR 34.9%

52-week position4% through range

$0.27$0.72

News mentions2

Community mentions0partial coverage

U.S.-scope patents18

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal84/100
Management stability90/100
Market position3/100
Capital-event signal31/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4ARCT · Nasdaq

Arcturus Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2013San Diego, California$431.7M market cap

View full Companies Radar profile

37Cautious

Snapshot price$15.19as of page date

Monthly-close return-70.5%five-year window

FY2025 revenue$0.08BArcturus Therapeutics Holdings Inc.

Net margin-80.2%FY2025

P/E snapshot-4.1xone ratio, not a verdict

Prism attention46.3%share across these five

Filing track recordRevenue, USD billions

+563.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 60.5%

52-week position52% through range

$5.50$24.17

News mentions3.2K

Community mentions0partial coverage

U.S.-scope patents491

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal40/100
Management stability90/100
Market position5/100
Capital-event signal39/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5SIGA · Nasdaq

SIGA Technologies

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1995New York City, New York$219.9M market cap

View full Companies Radar profile

37Cautious

Snapshot price$3.06as of page date

Monthly-close return-53.1%five-year window

FY2025 revenue$0.10BSIGA TECHNOLOGIES INC

Net margin24.6%FY2025

P/E snapshot2.8xone ratio, not a verdict

Prism attention10.8%share across these five

Filing track recordRevenue, USD billions

-29.2%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -8.3%

52-week position3% through range

$2.83$9.45

News mentions748

Community mentions43partial coverage

U.S.-scope patents279

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal30/100
Management stability90/100
Market position7/100
Capital-event signal42/100
Innovation pulse13/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 27 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 4 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Elite Pharma

+480.0%

Cytokinetics

+136.3%

Nurix Therapeutics

-16.5%

SIGA Technologies

-53.1%

Arcturus Therapeutics

-70.5%

Latest revenue

USD billions, official filing scope shown on each company card.

SIGA Technologies

$0.10B

Cytokinetics

$0.09B

Nurix Therapeutics

$0.08B

Elite Pharma

$0.08B

Arcturus Therapeutics

$0.08B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

SIGA Technologies

24.6%

Elite Pharma

-5.1%

Arcturus Therapeutics

-80.2%

Nurix Therapeutics

-314.9%

Cytokinetics

-891.6%

Prism news attention

Normalized share across these five names; attention is not quality.

Arcturus Therapeutics

46.3%

Cytokinetics

29.7%

Nurix Therapeutics

13.2%

SIGA Technologies

10.8%

Elite Pharma

0.0%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Arcturus Therapeutics leads the conversation

It holds 46.3% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.08B.

Price path

Elite Pharma leads the available price paths

Its monthly-close return is +480.0% for the five-year window. At the other end, Arcturus Therapeutics is -70.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

SIGA Technologies has the widest latest margin

Its FY2025 net margin is 24.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Nurix Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -18.2x while its five-year window price return is -16.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CYTK

Cytokinetics

2,053available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+3.4%366 latest 12m vs 354 prior 12m

Machine-classified coverage tone

77.2% positive-11.4 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

heart failure medications 38hypertrophic cardiomyopathy 33arrhythmogenic rv cardiomyopathy 29iron overload cardiomyopathy 28dilated cardiomyopathy 27stock performance 25treasury shares 24cardiac resynchronization therapy 13

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · NRIX

Nurix Therapeutics

910available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-3.0%226 latest 12m vs 233 prior 12m

Machine-classified coverage tone

92.6% positive-6.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

checkpoint inhibitors lymphoma 24antibody-drug conjugates lymphoma 21lymphoplasmacytic lymphoma 17stock performance 16t-cell lymphoma 13angiogenesis inhibitors 13cell-based therapies 13cancer biomarkers 12

Keyword tag occurrences in available Prism news records.

Coverage: 2013-05-01–2026-06-13 · trend and themes shown through 2026-06

Areas of research · ARCT

Arcturus Therapeutics

3,204available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Earnings & financial performance

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-13.9%353 latest 12m vs 410 prior 12m

Machine-classified coverage tone

90.4% positive-2.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

astrometry 57star formation regions 37meteor observations 36stellar remnants 36stellar evolution 35meteor showers 33cometary activity 31cometary outbursts 30

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-16 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SIGA

SIGA Technologies

43 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 43 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CYTK

Cytokinetics

through 2026-02-03

Earnings releases 11Company announcements 5Listing / IPO 5Leadership changes 3M&A 2

2026-02-03
Earnings releases
Based on Cytokinetics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.94 million and a GAAP net loss of $306.18 million.
2026-01-20
Company announcements
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees.
2025-11-10
Lawsuits
A shareholder class action lawsuit has been filed against Cytokinetics, Incorporated (“Cytokinetics” or the “Company”).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NRIX

Nurix Therapeutics

through 2026-04-07

Earnings releases 11Company announcements 7Listing / IPO 4Regulatory 2Leadership changes 1

2026-04-07
Earnings releases
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is projected to issue its Q1 2026 results before the market opens on Tuesday, April 14th.
2025-11-10
Leadership changes
On November 6, 2025, Nurix Therapeutics appointed Roger Dansey, M.D., to its board of directors and as a member of the Clinical and Commercialization Committee.
2025-06-16
Company announcements
Nurix Therapeutics, Inc. (Nasdaq: NRIX), ... today announced that on June 10, 2025, the company granted inducement awards to seventeen new employees.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ELTP

Elite Pharma

through 2026-02-17

Earnings releases 17Leadership changes 2

2026-02-17
Earnings releases
Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million , an increase of $17.2 million or approximately 120% as compared to the comparable period of the prior fiscal year. Income from operations was $9.0 million , an increase of $7.9 million or approximately 721% , as compared to the comparable period of the prior fiscal year. Net income was $18.6 million.
2023-09-07
Leadership changes
today announced the appointment of Carter Ward as its Chief Financial Officer (CFO), effective September 5, 2023.
2026-02-12
Earnings releases
Elite Pharmaceuticals, Inc. (OTCQB: ELTP) (“Elite” or the “Company”), announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ARCT

Arcturus Therapeutics

through 2026-04-27

Earnings releases 11Company announcements 2Business contracts 1Leadership changes 1Regulatory 1

2026-04-27
Earnings releases
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT ), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will release its financial results for the quarter ended March 31, 2026 after the market close on Thursday, May 7 th and will also host a conference call and webcast at 4:30 pm Eastern Time on May 7, 2026.
2025-05-14
Company announcements
Arcturus Therapeutics is scaling back work on early-stage candidates and will instead dedicate its resources to its more developed mRNA therapies, the biotech announced Tuesday alongside its first-quarter earnings report.
2025-02-14
Business contracts
Arcturus Therapeutics Ltd., of San Diego, said it is extending its partnership with Tokyo-based Takeda Pharmaceutical Co. Ltd. The partners will advance their efforts to develop RNA‑based therapeutics for the treatment of nonalcoholic steatohepatitis and other gastrointestinal-related disorders using Arcturus' lipid‑enabled and unlocked nucleomonomer agent modified RNA delivery systems and unlocked nucleomonomer agent oligomer chemistry.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SIGA

SIGA Technologies

through 2026-04-01

Earnings releases 23Company announcements 13Leadership changes 5Business contracts 4Lawsuits 3

2026-04-01
Earnings releases
Siga Technologies $94.57 million 4.05 $23.28 million $0.31 17.26
2026-03-03
Company announcements
SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 10, 2026.
2025-02-14
Listing / IPO
Siga Technologies Inc., of New York, began a rights offering for gross proceeds of about $35 million, which will be used to satisfy the remaining portion of Annapolis, Md.-based Pharmathene Inc.'s judgment against the company following a long-running dispute over smallpox antiviral tecovirimat.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence

2011 extracted base$66.70B

2016 extracted forecast$42.00B–$70.00B

Implied source CAGR9.5%

Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records

Latest 12m volume+3.4%24052 vs 23272 records

Positive classified tone65.3%+6.0 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies

6,223

snowstorm and blizzard alerts

6,121

pharmaceutical marketing and sales strategies

6,014

winter weather preparedness

5,925

generic drug development and market trends

3,700

healthcare economics and market access

3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 61–68. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cytokinetics leads the readiness ranking

Its Prism readiness score is 58/100, the highest in this five-company comparison.

Open Cytokinetics in Companies Radar

Scale and margin leadership sit with SIGA Technologies and SIGA Technologies

SIGA Technologies has the largest displayed latest revenue at $0.10B; SIGA Technologies has the widest displayed latest margin at 24.6%.

Open SIGA Technologies in Companies Radar

Comparisons

Strongest versus weakest available price path

Elite Pharma is +480.0% for its five-year window; Arcturus Therapeutics is -70.5% for its five-year window.

Open Elite Pharma in Companies Radar Open Arcturus Therapeutics in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.10B for SIGA Technologies to $0.08B for Arcturus Therapeutics. Entity and filing-period labels remain visible on the company cards.

Open SIGA Technologies in Companies Radar Open Arcturus Therapeutics in Companies Radar

Anomalies

Arcturus Therapeutics has the widest attention-readiness rank gap

It ranks #1 by measured news attention (46.3%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Arcturus Therapeutics in Companies Radar

Arcturus Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +563.7% while its available monthly-close return is -70.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Arcturus Therapeutics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Arcturus Therapeutics's 46.3% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Arcturus Therapeutics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cytokinetics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 58/100 score.

Open Cytokinetics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Arcturus Therapeutics's profile with Elite Pharma's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Arcturus Therapeutics in Companies Radar Open Elite Pharma in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.